35.168.110.128
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Glaucoma

Bimatoprost implant reduces need for rescue treatment in investigational study

Posted on February 22, 2021

Patients had an 80% probability of requiring no IOP-lowering treatment for more than 1 year after the third administration of bimatoprost implant 10μg (BimSR, Durysta, AbbVie Inc.), according to a poster study presented at 2020 AAO Virtual.

Baseline IOP >25 mmHg, prior selective laser trabeculoplasty (SLT), male gender, pseudophakic status, and IOP increase or reduction ≤5 mmHg before the third administration were significantly associated with rescue.

For the study, the researchers set out to identify factors associated with need for rescue IOP-lowering treatment after a third bimatoprost implant 10 μg administration (day 1, weeks 16 and 32) in the 20-month phase 3 ARTEMIS studies. They conducted a multivariable Cox regression analysis of time to first use of rescue for open-angle glaucoma and ocular hypertension (OAG/OHT) patients randomized to the bimatoprost implant. Nineteen percent of patients (61/326), required rescue after third implant administration.

The bimatoprost implant 10 μg is approved for single administration. Registration studies are ongoing to potentially allow for implant re-administration. This analysis of predictive factors for long-term IOP lowering in the phase 3 studies is directional, and additional clinical studies are necessary to further understand patient characteristics predictive of a sustained response to a single administration, the researchers concluded.  

Reference
Khouri AS, et al. Predictive factors for long-term IOP-lowering after bimatoprost implant 10-μg administration in phase 3 ARTEMIS studies. Presented at: AAO 2020 Virtual [Session: PO176].

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-